Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors.

D'Angelica M, Karpoff H, Halterman M, Ellis J, Klimstra D, Edelstein D, Brownlee M, Federoff H, Fong Y.

Cancer Immunol Immunother. 1999 Jan;47(5):265-71.

PMID:
10022470
2.

Efficient cotransduction of tumors by multiple herpes simplex vectors: implications for tumor vaccine production.

Karpoff HM, Kooby D, D'Angelica M, Mack J, Presky DH, Brownlee MD, Federoff H, Fong Y.

Cancer Gene Ther. 2000 Apr;7(4):581-8.

3.

Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: implications for local gene therapy.

Brooks AD, Ng B, Liu D, Brownlee M, Burt M, Federoff HJ, Fong Y.

Surgery. 2001 Mar;129(3):324-34.

PMID:
11231461
4.

Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer.

Kwong YL, Chen SH, Kosai K, Finegold M, Woo SL.

Chest. 1997 Nov 5;112(5):1332-7.

PMID:
9367477
5.

Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production.

Tung C, Federoff HJ, Brownlee M, Karpoff H, Weigel T, Brennan MF, Fong Y.

Hum Gene Ther. 1996 Dec 1;7(18):2217-24.

PMID:
8953312
6.

In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors.

Ram Z, Walbridge S, Heiss JD, Culver KW, Blaese RM, Oldfield EH.

J Neurosurg. 1994 Mar;80(3):535-40.

PMID:
8113867
7.

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma.

Wong RJ, Patel SG, Kim S, DeMatteo RP, Malhotra S, Bennett JJ, St-Louis M, Shah JP, Johnson PA, Fong Y.

Hum Gene Ther. 2001 Feb 10;12(3):253-65.

PMID:
11177562
8.

In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats.

Ram Z, Culver KW, Walbridge S, Blaese RM, Oldfield EH.

Cancer Res. 1993 Jan 1;53(1):83-8.

9.

Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector.

Carew JF, Federoff H, Halterman M, Kraus DH, Savage H, Sacks PG, Schantz SP, Shah JP, Fong Y.

Am J Surg. 1998 Nov;176(5):404-8.

PMID:
9874422
10.

Improved herpes simplex virus type 1 amplicon vectors for proportional coexpression of positron emission tomography marker and therapeutic genes.

Jacobs AH, Winkeler A, Hartung M, Slack M, Dittmar C, Kummer C, Knoess C, Galldiks N, Vollmar S, Wienhard K, Heiss WD.

Hum Gene Ther. 2003 Feb 10;14(3):277-97.

PMID:
12639307
11.

A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes.

Carew JF, Kooby DA, Halterman MW, Kim SH, Federoff HJ, Fong Y.

Mol Ther. 2001 Sep;4(3):250-6.

12.

Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.

Zager JS, Delman KA, Malhotra S, Ebright MI, Bennett JJ, Kates T, Halterman M, Federoff H, Fong Y.

Mol Med. 2001 Aug;7(8):561-8.

13.

In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.

J Gene Med. 2004 Mar;6(3):288-99.

PMID:
15026990
14.

Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors.

Kramm CM, Rainov NG, Sena-Esteves M, Chase M, Pechan PA, Chiocca EA, Breakefield XO.

Hum Gene Ther. 1996 Feb 10;7(3):291-300.

PMID:
8835217
15.

Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors.

Vincent AJ, Vogels R, Someren GV, Esandi MC, Noteboom JL, Avezaat CJ, Vecht C, Bekkum DW, Valerio D, Bout A, Hoogerbrugge PM.

Hum Gene Ther. 1996 Jan 20;7(2):197-205.

PMID:
8788170
16.

Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.

Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA.

Gene Ther. 1994 Sep;1(5):323-31.

PMID:
7584098
17.

Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.

Fraefel C, Jacoby DR, Lage C, Hilderbrand H, Chou JY, Alt FW, Breakefield XO, Majzoub JA.

Mol Med. 1997 Dec;3(12):813-25.

18.

Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.

Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG.

Cancer Res. 2001 Apr 1;61(7):2983-95.

19.

Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model.

Majumdar AS, Zolotorev A, Samuel S, Tran K, Vertin B, Hall-Meier M, Antoni BA, Adeline E, Philip M, Philip R.

Cancer Gene Ther. 2000 Jul;7(7):1086-99.

20.

Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer.

Barzon L, Bonaguro R, Castagliuolo I, Chilosi M, Gnatta E, Parolin C, Boscaro M, Pal├╣ G.

J Clin Endocrinol Metab. 2002 Nov;87(11):5304-11.

PMID:
12414907

Supplemental Content

Support Center